Compare Infosys Limited (INFY) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Inovio Pharmaceuticals Inc — how do they compare? Infosys Limited trades at $10.73 (market cap $41.74B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Infosys Limited is far larger — about 372× Inovio Pharmaceuticals Inc's market cap, and Infosys Limited pays a 4.89% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| INFY | INO | |
|---|---|---|
Market Cap | $41.74B | $112.19M |
Volume | 31,354,285 | 3,201,278 |
Sector | Technology | Health |
52-Week High | $20.22 | $2.60 |
52-Week Low | $10.49 | $0.66 |
Typical Hold Time | 27 Days | 43 Days |
Enterprise Value | $39.48B | $83.51M |
Dividend Yield | 4.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.70, up 1.42% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong profitability with a 16.37% net income margin and ROE of 32.12%. Recent news highlights strategic AI collaborations with Columbia University and ABN Amro. Earnings history shows mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026.
The outlook is cautiously optimistic with a consensus price target of $11.48, offering potential upside. Risks include competitive pressures in IT services and volatile cash flow trends, with net cash flow turning negative in 2026. Analyst sentiment is mixed, with 35% buy ratings but 55% hold, reflecting uncertainty amid steady fundamentals.
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
